Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$380K Sell
3,156
-665
-17% -$76.8K 0.23% 80
2025
Q4
$402K Sell
3,821
-875
-19% -$82.1K 0.26% 83
2025
Q3
$394K Buy
4,696
+745
+19% +$61.4K 0.27% 83
2025
Q2
$313K Buy
3,951
+650
+20% +$51.7K 0.28% 92
2025
Q1
$296K Sell
3,301
-474
-13% -$44.3K 0.29% 91
2024
Q4
$376K Sell
3,775
-712
-16% -$73.4K 0.25% 90
2024
Q3
$442K Buy
4,487
+4,292
+2,201% +$510K 0.28% 85
2024
Q2
$24.1K Sell
195
-3,863
-95% -$498K 0.02% 335
2024
Q1
$535K Buy
4,058
+80
+2% +$9.86K 0.4% 57
2023
Q4
$437K Buy
+3,978
New +$413K 0.36% 63

Other funds holding MRK

Caitlin John's MRK Position: Q1 2026 in Review

Caitlin John reduced its Merck (MRK) stake by 17% in Q1 2026, selling an estimated $76.8K and leaving 3,156 shares worth $380K. The position accounts for 0.23% of the portfolio, ranked #80.

Caitlin John first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. The position peaked at $535K in Q1 2024. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Caitlin John held 3,156 shares of Merck worth $380K as of Q1 2026.
  • Caitlin John sold 665 Merck shares in Q1 2026, an estimated $76.8K.
  • Merck made up 0.23% of Caitlin John's portfolio in Q1 2026, its #80 holding.
  • Caitlin John first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • Caitlin John's Merck position peaked at $535K in Q1 2024.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.